Ark Therapeutics partnership achieves first milestone
Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.
Specialist healthcare group, Ark Therapeutics, and serious diseases therapies developer PsiOxus Therapeutics, said their partnership has successfully achieved its first milestone.
The firms have manufactured PsiOxus's colorectal cancer product, and as a result PsiOxus has initiated final pre-clinical toxicology studies of the product.
Martyn Williams, Chief Executive Officer of Ark said: "We are delighted that our early success with ColoAd1 will enable the development of this exciting product to move forward as planned and we look forward to continuing to provide full support to our partner as their programme moves into the clinic."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The share price rose 4.69% to 3.35p by 15:17.
__
NR
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Inheritance tax reforms: government urged to rethink curbs on rural reliefs
MPs want the government to delay changes to inheritance rax reliefs for farmers
-
‘I’m among the thousands of millionaires leaving the UK – the new tax rules don’t make sense ’
MoneyWeek spoke to a serial entrepreneur who is leaving the UK following the abolition of the non-dom tax status